This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Halozyme Therapeutics, Inc.
Drug Names(s): Adalimumab rHuPH20 ENHANZE
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).
Halozyme's proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. When injected under the skin, rHuPH20 transiently generates channels in tissues underlying the outer layers of the skin to increase the absorption and spread of injected drugs.
Halozyme and Abbvie
In June 2015, Halozyme Therapeutics announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform. Under the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling approximately $130 million for each of up to nine collaboration targets. These payments are subject to AbbVie's achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay Halozyme tiered royalties if products under the collaboration are commercialized.
Partners: AbbVie Inc.
Adalimumab-rHuPH20 (Subcutaneous) News
Additional information available to subscribers only: